Initiating apoptosis in tumour cells through methods involving the augmentation of CD95 signalling is a treatment avenue that has been explored, mostly unsuccessfully, for a number of years10 but a large swathe of evidence exists suggesting that chemotherapies sensitise tumours to CD95/FasL killing11,12 and CD95 has been shown to be upregulated upon cells after treatment with a number of chemotherapeutics including: doxorubicin, cisplatin, mitomycin C, 5-FU, dacarbazine and gemcitabine13,14. This evidence concerns the gene FAS and neoplasm.